The North America Diabetes Care Devices Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).
Over the last few decades, the use of technology for diabetes treatment has increased, particularly among young and middle-aged individuals with type 1 diabetes. Technology's use has spread to people with type 2 diabetes as it has become more prevalent, less expensive, as well as easier to use. In addition, an increasing population of elderly have begun to use technology to manage their diabetes in recent years. Currently, significant advancements in diabetes technology include insulin delivery methods, (such as smart insulin pens and insulin pumps blood), glucose monitoring (such as CGM), and hybrid devices, which integrate glucose monitoring and insulin delivery systems. The ultimate purpose of using these technologies is to enhance glycemic management, minimize hypoglycemia risk, lessen the burden of diabetes, and enhanced the quality of life.
Blood glucose monitoring reveals how much and when a patient's body needs insulin. Blood sugar levels that fluctuate a lot can harm patients' health in a variety of ways. When blood sugar levels are too high (hyperglycemia) or too low (hypoglycemia), they can be dangerous and even fatal. Blood sugar levels can be affected by a variety of factors, including the meals a patient eats and their lifestyle. However, diabetes affects everyone differently. The impact of a food or exercise on one person's glucose levels is frequently different from that of another.
A blood sugar meter, also called a blood glucose meter or glucometer, is a portable electronic device used to measure the blood sugar in real-time to ensure it is not too high or too low. A sample of the blood is drawn on a blood lancet, an equipment that quickly pricks the skin. Place a drop on the disposable diabetic test strip's edge. Post the process, the amount of blood sugar is displayed on the monitor.
According to the National Center of Biotechnology Information, angiotensin-converting enzyme inhibitors are used to treat diabetes, and it has been shown that coronavirus binds to target cells via this enzyme, which is found in the blood vessels and lungs. As the level of the ACE2 enzyme in diabetic people rises, so do their chances of contracting COVID-19. Moreover, according to the Diabetes Research Organization, diabetes affects 34.2 million Americans or 10.5% of the population. Diabetes has been diagnosed in an estimated 26.8 million people or 10.2% of the population. In 2018, 7.3 million people in the United States had diabetes but have not been diagnosed. Diabetes affects people from all socioeconomic, economic, and ethnic groups. Type 1 diabetes affects approximately 1.6 million people and accounts for about 5.2% of all diagnosed cases of diabetes.
The US market dominated the North America Diabetes Care Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8,197.6 Million by 2028. The Canada market is poised to grow at a CAGR of 7.5% during (2022 - 2028). Additionally, The Mexico market would display a CAGR of 6.5% during (2022 - 2028).
Based on Product, the market is segmented into Insulin Delivery Devices and Blood Glucose Monitoring Devices. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Diabetes Care Devices Market is Estimated to reach $29.3 Billion by 2028, at a CAGR of 6.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, Sanofi S.A., Zealand Pharma A/S, B. Braun Melsungen AG, Bayer AG, Abbott Laboratories, Ypsomed AG, Arkray, Inc.
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
